Evaluation of fatty acid amides in the carrageenan-induced paw edema model

While it has long been recognized that Δ9-tetrahydrocannabinol (THC), the primary psychoactive constituent of cannabis, and other cannabinoid receptor agonists possess anti-inflammatory properties, their well known CNS effects have dampened enthusiasm for therapeutic development. On the other hand,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuropharmacology 2008-01, Vol.54 (1), p.181-188
Hauptverfasser: Wise, Laura E., Cannavacciulo, Roberta, Cravatt, Benjamin F., Martin, Billy F., Lichtman, Aron H.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 188
container_issue 1
container_start_page 181
container_title Neuropharmacology
container_volume 54
creator Wise, Laura E.
Cannavacciulo, Roberta
Cravatt, Benjamin F.
Martin, Billy F.
Lichtman, Aron H.
description While it has long been recognized that Δ9-tetrahydrocannabinol (THC), the primary psychoactive constituent of cannabis, and other cannabinoid receptor agonists possess anti-inflammatory properties, their well known CNS effects have dampened enthusiasm for therapeutic development. On the other hand, genetic deletion of fatty acid amide hydrolase (FAAH), the enzyme responsible for degradation of fatty acid amides, including endogenous cannabinoid N-arachidonoyl ethanolamine (anandamide; AEA), N-palmitoyl ethanolamine (PEA), N-oleoyl ethanolamine (OEA), and oleamide, also elicits anti-edema, but does not produce any apparent cannabinoid effects. The purpose of the present study was to investigate whether exogenous administration of FAAs would augment the anti-inflammatory phenotype of FAAH (−/−) mice in the carrageenan model. Thus, we evaluated the effects of the FAAs AEA, PEA, OEA, and oleamide in wild-type and FAAH (−/−) mice. For comparison, we evaluated the anti-edema effects of THC, dexamethasone (DEX), a synthetic glucocorticoid, diclofenac (DIC), a nonselective cyclooxygenase (COX) inhibitor, in both genotypes. A final study determined if tolerance to the anti-edema effects of PEA occurs after repeated dosing. PEA, THC, DEX, DIC elicited significant decreases in carrageenan-induced paw edema in wild-type mice. In contrast OEA produced a less reliable anti-edema effect than these other drugs, and AEA and oleamide failed to produce any significant decreases in paw edema. Moreover, none of the agents evaluated augmented the anti-edema phenotype of FAAH (−/−) mice, suggesting that maximal anti-edema effects had already been established. PEA was the most effective FAA in preventing paw edema and its effects did not undergo tolerance. While the present findings do not support a role for AEA in preventing carrageenan-induced edema, PEA administration and FAAH blockade elicited anti-edema effects of an equivalent magnitude as produced by THC, DEX, and DIC in this assay.
doi_str_mv 10.1016/j.neuropharm.2007.06.003
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2200792</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0028390807001736</els_id><sourcerecordid>17675189</sourcerecordid><originalsourceid>FETCH-LOGICAL-c477t-87a494181bb0e6d8d5920d48cfed6ad3df0ecc069293bfb3d2304f154b6a1e643</originalsourceid><addsrcrecordid>eNqFkMtOwzAQRS0EouXxC8g_kDBOXMfZIEFVXqrEBtbWxJ5QV41TOWlR_55URTxWrGYx99wrHca4gFSAUNfLNNAmtusFxibNAIoUVAqQH7Gx0EWeFKDkMRsDZDrJS9AjdtZ1SwCQWuhTNhKFKiZCl2P2PNviaoO9bwNva15j3-84Wu84Nt5Rx33g_YK4xRjxnShgSHxwG0uOr_GDk6MGedM6Wl2wkxpXHV1-3XP2dj97nT4m85eHp-ntPLGyKPpEFyhLKbSoKiDltJuUGTipbU1OoctdDWQtqDIr86qucpflIGsxkZVCQUrm5-zm0LveVA05S6GPuDLr6BuMO9OiN38_wS_Me7s12d5UmQ0F-lBgY9t1kepvVoDZ-zVL8-PX7CkDygx-B_Tq9_YP-CV0CNwdAjQY2HqKprOewqDLR7K9ca3_f-UTEviTyg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Evaluation of fatty acid amides in the carrageenan-induced paw edema model</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Wise, Laura E. ; Cannavacciulo, Roberta ; Cravatt, Benjamin F. ; Martin, Billy F. ; Lichtman, Aron H.</creator><creatorcontrib>Wise, Laura E. ; Cannavacciulo, Roberta ; Cravatt, Benjamin F. ; Martin, Billy F. ; Lichtman, Aron H.</creatorcontrib><description>While it has long been recognized that Δ9-tetrahydrocannabinol (THC), the primary psychoactive constituent of cannabis, and other cannabinoid receptor agonists possess anti-inflammatory properties, their well known CNS effects have dampened enthusiasm for therapeutic development. On the other hand, genetic deletion of fatty acid amide hydrolase (FAAH), the enzyme responsible for degradation of fatty acid amides, including endogenous cannabinoid N-arachidonoyl ethanolamine (anandamide; AEA), N-palmitoyl ethanolamine (PEA), N-oleoyl ethanolamine (OEA), and oleamide, also elicits anti-edema, but does not produce any apparent cannabinoid effects. The purpose of the present study was to investigate whether exogenous administration of FAAs would augment the anti-inflammatory phenotype of FAAH (−/−) mice in the carrageenan model. Thus, we evaluated the effects of the FAAs AEA, PEA, OEA, and oleamide in wild-type and FAAH (−/−) mice. For comparison, we evaluated the anti-edema effects of THC, dexamethasone (DEX), a synthetic glucocorticoid, diclofenac (DIC), a nonselective cyclooxygenase (COX) inhibitor, in both genotypes. A final study determined if tolerance to the anti-edema effects of PEA occurs after repeated dosing. PEA, THC, DEX, DIC elicited significant decreases in carrageenan-induced paw edema in wild-type mice. In contrast OEA produced a less reliable anti-edema effect than these other drugs, and AEA and oleamide failed to produce any significant decreases in paw edema. Moreover, none of the agents evaluated augmented the anti-edema phenotype of FAAH (−/−) mice, suggesting that maximal anti-edema effects had already been established. PEA was the most effective FAA in preventing paw edema and its effects did not undergo tolerance. While the present findings do not support a role for AEA in preventing carrageenan-induced edema, PEA administration and FAAH blockade elicited anti-edema effects of an equivalent magnitude as produced by THC, DEX, and DIC in this assay.</description><identifier>ISSN: 0028-3908</identifier><identifier>EISSN: 1873-7064</identifier><identifier>DOI: 10.1016/j.neuropharm.2007.06.003</identifier><identifier>PMID: 17675189</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Amidohydrolases - deficiency ; Analysis of Variance ; Animals ; Arachidonic Acids - metabolism ; Cannabinoids - metabolism ; Carrageenan ; Dexamethasone - therapeutic use ; Disease Models, Animal ; Dose-Response Relationship, Drug ; Dronabinol - therapeutic use ; Drug Interactions ; Edema ; Edema - chemically induced ; Edema - drug therapy ; Edema - genetics ; Edema - metabolism ; Endocannabinoids ; Endogenous cannabinoid ; Ethanolamines - metabolism ; Fatty acid amide hydrolase (FAAH) ; Female ; Inflammation ; Male ; Mice ; Mice, Inbred C57BL ; Mice, Knockout ; N-Arachidonoyl ethanolamine (anandamide) ; N-Palmitoyl ethanolamine (PEA) ; Oleic Acids - metabolism ; Polyunsaturated Alkamides - metabolism ; THC</subject><ispartof>Neuropharmacology, 2008-01, Vol.54 (1), p.181-188</ispartof><rights>2007 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c477t-87a494181bb0e6d8d5920d48cfed6ad3df0ecc069293bfb3d2304f154b6a1e643</citedby><cites>FETCH-LOGICAL-c477t-87a494181bb0e6d8d5920d48cfed6ad3df0ecc069293bfb3d2304f154b6a1e643</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0028390807001736$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17675189$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wise, Laura E.</creatorcontrib><creatorcontrib>Cannavacciulo, Roberta</creatorcontrib><creatorcontrib>Cravatt, Benjamin F.</creatorcontrib><creatorcontrib>Martin, Billy F.</creatorcontrib><creatorcontrib>Lichtman, Aron H.</creatorcontrib><title>Evaluation of fatty acid amides in the carrageenan-induced paw edema model</title><title>Neuropharmacology</title><addtitle>Neuropharmacology</addtitle><description>While it has long been recognized that Δ9-tetrahydrocannabinol (THC), the primary psychoactive constituent of cannabis, and other cannabinoid receptor agonists possess anti-inflammatory properties, their well known CNS effects have dampened enthusiasm for therapeutic development. On the other hand, genetic deletion of fatty acid amide hydrolase (FAAH), the enzyme responsible for degradation of fatty acid amides, including endogenous cannabinoid N-arachidonoyl ethanolamine (anandamide; AEA), N-palmitoyl ethanolamine (PEA), N-oleoyl ethanolamine (OEA), and oleamide, also elicits anti-edema, but does not produce any apparent cannabinoid effects. The purpose of the present study was to investigate whether exogenous administration of FAAs would augment the anti-inflammatory phenotype of FAAH (−/−) mice in the carrageenan model. Thus, we evaluated the effects of the FAAs AEA, PEA, OEA, and oleamide in wild-type and FAAH (−/−) mice. For comparison, we evaluated the anti-edema effects of THC, dexamethasone (DEX), a synthetic glucocorticoid, diclofenac (DIC), a nonselective cyclooxygenase (COX) inhibitor, in both genotypes. A final study determined if tolerance to the anti-edema effects of PEA occurs after repeated dosing. PEA, THC, DEX, DIC elicited significant decreases in carrageenan-induced paw edema in wild-type mice. In contrast OEA produced a less reliable anti-edema effect than these other drugs, and AEA and oleamide failed to produce any significant decreases in paw edema. Moreover, none of the agents evaluated augmented the anti-edema phenotype of FAAH (−/−) mice, suggesting that maximal anti-edema effects had already been established. PEA was the most effective FAA in preventing paw edema and its effects did not undergo tolerance. While the present findings do not support a role for AEA in preventing carrageenan-induced edema, PEA administration and FAAH blockade elicited anti-edema effects of an equivalent magnitude as produced by THC, DEX, and DIC in this assay.</description><subject>Amidohydrolases - deficiency</subject><subject>Analysis of Variance</subject><subject>Animals</subject><subject>Arachidonic Acids - metabolism</subject><subject>Cannabinoids - metabolism</subject><subject>Carrageenan</subject><subject>Dexamethasone - therapeutic use</subject><subject>Disease Models, Animal</subject><subject>Dose-Response Relationship, Drug</subject><subject>Dronabinol - therapeutic use</subject><subject>Drug Interactions</subject><subject>Edema</subject><subject>Edema - chemically induced</subject><subject>Edema - drug therapy</subject><subject>Edema - genetics</subject><subject>Edema - metabolism</subject><subject>Endocannabinoids</subject><subject>Endogenous cannabinoid</subject><subject>Ethanolamines - metabolism</subject><subject>Fatty acid amide hydrolase (FAAH)</subject><subject>Female</subject><subject>Inflammation</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Mice, Knockout</subject><subject>N-Arachidonoyl ethanolamine (anandamide)</subject><subject>N-Palmitoyl ethanolamine (PEA)</subject><subject>Oleic Acids - metabolism</subject><subject>Polyunsaturated Alkamides - metabolism</subject><subject>THC</subject><issn>0028-3908</issn><issn>1873-7064</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMtOwzAQRS0EouXxC8g_kDBOXMfZIEFVXqrEBtbWxJ5QV41TOWlR_55URTxWrGYx99wrHca4gFSAUNfLNNAmtusFxibNAIoUVAqQH7Gx0EWeFKDkMRsDZDrJS9AjdtZ1SwCQWuhTNhKFKiZCl2P2PNviaoO9bwNva15j3-84Wu84Nt5Rx33g_YK4xRjxnShgSHxwG0uOr_GDk6MGedM6Wl2wkxpXHV1-3XP2dj97nT4m85eHp-ntPLGyKPpEFyhLKbSoKiDltJuUGTipbU1OoctdDWQtqDIr86qucpflIGsxkZVCQUrm5-zm0LveVA05S6GPuDLr6BuMO9OiN38_wS_Me7s12d5UmQ0F-lBgY9t1kepvVoDZ-zVL8-PX7CkDygx-B_Tq9_YP-CV0CNwdAjQY2HqKprOewqDLR7K9ca3_f-UTEviTyg</recordid><startdate>20080101</startdate><enddate>20080101</enddate><creator>Wise, Laura E.</creator><creator>Cannavacciulo, Roberta</creator><creator>Cravatt, Benjamin F.</creator><creator>Martin, Billy F.</creator><creator>Lichtman, Aron H.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20080101</creationdate><title>Evaluation of fatty acid amides in the carrageenan-induced paw edema model</title><author>Wise, Laura E. ; Cannavacciulo, Roberta ; Cravatt, Benjamin F. ; Martin, Billy F. ; Lichtman, Aron H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c477t-87a494181bb0e6d8d5920d48cfed6ad3df0ecc069293bfb3d2304f154b6a1e643</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Amidohydrolases - deficiency</topic><topic>Analysis of Variance</topic><topic>Animals</topic><topic>Arachidonic Acids - metabolism</topic><topic>Cannabinoids - metabolism</topic><topic>Carrageenan</topic><topic>Dexamethasone - therapeutic use</topic><topic>Disease Models, Animal</topic><topic>Dose-Response Relationship, Drug</topic><topic>Dronabinol - therapeutic use</topic><topic>Drug Interactions</topic><topic>Edema</topic><topic>Edema - chemically induced</topic><topic>Edema - drug therapy</topic><topic>Edema - genetics</topic><topic>Edema - metabolism</topic><topic>Endocannabinoids</topic><topic>Endogenous cannabinoid</topic><topic>Ethanolamines - metabolism</topic><topic>Fatty acid amide hydrolase (FAAH)</topic><topic>Female</topic><topic>Inflammation</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Mice, Knockout</topic><topic>N-Arachidonoyl ethanolamine (anandamide)</topic><topic>N-Palmitoyl ethanolamine (PEA)</topic><topic>Oleic Acids - metabolism</topic><topic>Polyunsaturated Alkamides - metabolism</topic><topic>THC</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wise, Laura E.</creatorcontrib><creatorcontrib>Cannavacciulo, Roberta</creatorcontrib><creatorcontrib>Cravatt, Benjamin F.</creatorcontrib><creatorcontrib>Martin, Billy F.</creatorcontrib><creatorcontrib>Lichtman, Aron H.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Neuropharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wise, Laura E.</au><au>Cannavacciulo, Roberta</au><au>Cravatt, Benjamin F.</au><au>Martin, Billy F.</au><au>Lichtman, Aron H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of fatty acid amides in the carrageenan-induced paw edema model</atitle><jtitle>Neuropharmacology</jtitle><addtitle>Neuropharmacology</addtitle><date>2008-01-01</date><risdate>2008</risdate><volume>54</volume><issue>1</issue><spage>181</spage><epage>188</epage><pages>181-188</pages><issn>0028-3908</issn><eissn>1873-7064</eissn><abstract>While it has long been recognized that Δ9-tetrahydrocannabinol (THC), the primary psychoactive constituent of cannabis, and other cannabinoid receptor agonists possess anti-inflammatory properties, their well known CNS effects have dampened enthusiasm for therapeutic development. On the other hand, genetic deletion of fatty acid amide hydrolase (FAAH), the enzyme responsible for degradation of fatty acid amides, including endogenous cannabinoid N-arachidonoyl ethanolamine (anandamide; AEA), N-palmitoyl ethanolamine (PEA), N-oleoyl ethanolamine (OEA), and oleamide, also elicits anti-edema, but does not produce any apparent cannabinoid effects. The purpose of the present study was to investigate whether exogenous administration of FAAs would augment the anti-inflammatory phenotype of FAAH (−/−) mice in the carrageenan model. Thus, we evaluated the effects of the FAAs AEA, PEA, OEA, and oleamide in wild-type and FAAH (−/−) mice. For comparison, we evaluated the anti-edema effects of THC, dexamethasone (DEX), a synthetic glucocorticoid, diclofenac (DIC), a nonselective cyclooxygenase (COX) inhibitor, in both genotypes. A final study determined if tolerance to the anti-edema effects of PEA occurs after repeated dosing. PEA, THC, DEX, DIC elicited significant decreases in carrageenan-induced paw edema in wild-type mice. In contrast OEA produced a less reliable anti-edema effect than these other drugs, and AEA and oleamide failed to produce any significant decreases in paw edema. Moreover, none of the agents evaluated augmented the anti-edema phenotype of FAAH (−/−) mice, suggesting that maximal anti-edema effects had already been established. PEA was the most effective FAA in preventing paw edema and its effects did not undergo tolerance. While the present findings do not support a role for AEA in preventing carrageenan-induced edema, PEA administration and FAAH blockade elicited anti-edema effects of an equivalent magnitude as produced by THC, DEX, and DIC in this assay.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>17675189</pmid><doi>10.1016/j.neuropharm.2007.06.003</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0028-3908
ispartof Neuropharmacology, 2008-01, Vol.54 (1), p.181-188
issn 0028-3908
1873-7064
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2200792
source MEDLINE; Elsevier ScienceDirect Journals
subjects Amidohydrolases - deficiency
Analysis of Variance
Animals
Arachidonic Acids - metabolism
Cannabinoids - metabolism
Carrageenan
Dexamethasone - therapeutic use
Disease Models, Animal
Dose-Response Relationship, Drug
Dronabinol - therapeutic use
Drug Interactions
Edema
Edema - chemically induced
Edema - drug therapy
Edema - genetics
Edema - metabolism
Endocannabinoids
Endogenous cannabinoid
Ethanolamines - metabolism
Fatty acid amide hydrolase (FAAH)
Female
Inflammation
Male
Mice
Mice, Inbred C57BL
Mice, Knockout
N-Arachidonoyl ethanolamine (anandamide)
N-Palmitoyl ethanolamine (PEA)
Oleic Acids - metabolism
Polyunsaturated Alkamides - metabolism
THC
title Evaluation of fatty acid amides in the carrageenan-induced paw edema model
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T01%3A22%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20fatty%20acid%20amides%20in%20the%20carrageenan-induced%20paw%20edema%20model&rft.jtitle=Neuropharmacology&rft.au=Wise,%20Laura%20E.&rft.date=2008-01-01&rft.volume=54&rft.issue=1&rft.spage=181&rft.epage=188&rft.pages=181-188&rft.issn=0028-3908&rft.eissn=1873-7064&rft_id=info:doi/10.1016/j.neuropharm.2007.06.003&rft_dat=%3Cpubmed_cross%3E17675189%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/17675189&rft_els_id=S0028390807001736&rfr_iscdi=true